SCRT Followed by AK112 in pMMR/MSS Mid-low Rectal Cancer

SCRT Followed by AK112 in pMMR/MSS Mid-low Rectal Cancer is a phase 2, interventional study registered as NCT07162714 by Zhejiang Cancer Hospital, with a registry enrolment figure of 30 participants, started 2025-10-27 and due to reach its primary completion in 2027-03-31. Interventions recorded: radiotherapy; Ivonescimab (20mg/kg Q3W); Non-operative Management; Surgery. Conditions listed: Rectal Cancer; Radiation; AK112. Primary outcome: Complete remission rate (CR rate). Colorectal eligibility wording from the registry: "Histopathologically confirmed rectal adenocarcinoma, without any prior anti - tumor treatment; The status of MMR/MSI is detected by IHC/PCR in pathological biopsy to clarify that the patient's classification is pMMR/MSS;". Sites: China. No results are recorded here; the registry entry is the source.